Sciele Pharma, Inc. is committed to continue its growth through business development initiatives – primarily licensing and acquiring products and/or companies. Licensing and acquiring late stage and commercialized products for sale in the United States are key to our near and long term success. To date, the Company has in-licensed or acquired products from companies including AstraZeneca, Bayer AG, Warner-Lambert, Sanofi-Aventis, Wyeth, Elan, SkyePharma, Andrx, Pohl-Boskamp, Biovail, Galephar, Addrenex, Summers Labs, Plethora Solutions, LifeCycle Pharma, and Novo Nordisk.

We are interested in opportunities in the following areas: cardiovascular, diabetes, women's health, pediatrics and products prescribed by primary care physicians. Additionally, we are interested in leveraging our current business model by licensing and acquiring products and/or companies in other specialty therapeutic areas. Sciele Pharma, Inc., headquartered in Atlanta, GA and founded in 1992, employs more than 900 people.

For further information, please contact Business Development at bd@sciele.com.

To inquire about opportunities to license and distribute Sciele’s products outside the United States, please contact Business Development at bd@sciele.com.

• Sciele Pharma Acquires Twinject(R) Epinephrine Auto-Injector from Verus Pharmaceuticals
• Sciele Expands Alliance with Sanofi-Aventis to Market Allegra(R) (Fexofenadine HCL) Orally Disintegrating Tablets (ODT) and Allegra(R) Oral Suspension (OS) in the U.S.
• Sciele Pharma to Acquire Alliant Pharmaceuticals, a Pediatric Specialty Pharmaceutical Company
• Sciele Enters Into Exclusive License Agreement with Plethora Solutions Limited to Market PSD502 for the Treatment of Premature Ejaculation
• Sciele Pharma Completes Acquisition of Alliant Pharmaceuticals
• Sciele Pharma Signs Agreement with Addrenex Pharmaceuticals to Market CLONICEL^®
• Sciele Pharma Acquires a Novel, Patented Treatment for Head Lice from Summers Laboratories, Inc.
  
• Sciele Signs Exclusive Agreement with Novo Nordisk to Market Prandin^® and PrandiMet^®